Combination Effect of Engineered Endolysin EC340 With Antibiotics
- 1LyseNTech Co., Ltd., Seongnam-si, South Korea
- 2Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin-si, South Korea
- 3The Bacteriophage Bank of Korea, Hankuk University of Foreign Studies, Yongin-si, South Korea
A corrigendum on
Combination effect of engineered endolysin EC340 with antibiotics
by Hong, H.-W., Kim, Y. D., Jang, J., Kim, M. S., Song, M., and Myung, H. (2022). Front. Microbiol. 13:821936. doi: 10.3389/fmicb.2022.821936
A correction has been made to Funding. In the original article a grant was mistakenly omitted. The corrected Funding statement appears below.
Funding
This work was supported by the National Research Foundation of Korea (Funds NRF-2017M3A9B8069292 and NRF-2019M3E5D5066666), the Korea Health Industry Development Institute (KHIDI) (HI21C2447), and HUFS Research Fund of 2021.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: endolysin, bacteriophage, Gram-negative bacteria, antibacterial agent, cecropin A, colistin, synergy
Citation: Hong H-W, Kim YD, Jang J, Kim MS, Song M and Myung H (2023) Corrigendum: Combination effect of engineered endolysin EC340 with antibiotics. Front. Microbiol. 14:1281242. doi: 10.3389/fmicb.2023.1281242
Received: 22 August 2023; Accepted: 23 August 2023;
Published: 31 August 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Hong, Kim, Jang, Kim, Song and Myung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Heejoon Myung, aGpteXVuZyYjeDAwMDQwO2h1ZnMuYWMua3I=